Nothing funny about fighting RCC it's a killer .My brother lost his battle last year August 13 He was i a good clinical trial with (Nivolumab) _- OPDIVO It gave him 2 years thats it ,so my hope is that something like this my work for others .I believe this is a good bet on Nobel Prize winner, Dr. Ralph Steinman. this Company's co-founder..I gambled with PCYC and won so i am playing with the house money.. P.S. I also own BMY,ABBV,and TGTX JMO
In the multicenter Phase 2 trial led by Dr. Asim Amin, medical oncologist at the Levine Cancer Institute, encouraging median overall survival of 30.2 months was observed for all patients treated with the combination of AGS-003 plus sunitinib. According to the International mRCC Database Consortium, similar unfavorable risk mRCC patients have an expected overall survival of 14.7 months. In addition, in the Phase 2 trial, patients with intermediate risk experienced a median survival in excess of 5 years.
Recently approved drugs such as Yervoy and Opdivo from Bristol Myers Squibb Co and Merck & Co Inc's Keytruda have helped some patients sustain remission. But those first-generation therapies do not work for everyone, and scientists are trying to understand how to make them more effective.
"Very little progress has been made over the last several decades," Parker said, referring to cancer drug research. "Average life expectancy has only increased three to six months with some of these drugs that cost billions to develop."
THREE KEY RESEARCH AREAS
The institute has identified three key areas of research - modifying a patient's own immune system T-cells to target a tumor; studying ways to boost patient response to current immunotherapy drugs; and research to identify other novel targets to attack a tumor.